Bavarian Nordic To Take Prostvac Prostate Cancer Vaccine Into Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bavarian Nordic's attempt to reduce the risk associated with developing a cancer vaccine includes licensing a vetted therapy from the National Cancer Institute and developing it with the institute under a Cooperative Research and Development Agreement.